During this webinar, Dr. Robert Bridwell discusses unmet imaging needs in recurrent and metastatic breast cancer, estrogen receptor heterogeneity, the value of Cerianna PET/CT, and appropriate patients to consider for its use.
Learning Objectives:
- Review the unmet imaging needs in recurrent and metastatic breast cancer
- Learn about estrogen receptor heterogeneity in metastatic breast cancer
- Recognize the value of Cerianna™ PET/CT and appropriate patients to consider for its use
- Review cases that demonstrate how determining full-body ER + lesions status may impact patient care.
Important Safety Information for Cerianna™ (fluoroestradiol F 18) Injection
INDICATIONS AND USAGE
CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.
Limitations of Use
Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesteronereceptor (PR).
CONTRAINDICATIONS
None.
ADVERSE REACTIONS
In Clinical Trials (n=1207) the most common adverse reactions seen occurred at a rate less than 1%: were injection-site pain and dysgeusia.
To report SUSPECTED ADVERSE REACTIONS, contact Zionexa US Corp at +1.844.946.6392 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
For full Prescribing Information: [ Ссылка ]
